NCT02397720View on ClinicalTrials.gov

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 7, 2015

Primary Completion Date

October 9, 2023

Study Completion Date

October 9, 2023

Conditions
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given SC or IV

DRUG

Ipilimumab

DRUG

Venetoclax

Given Orally

DRUG

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02397720 - Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter